Swiss National Bank Verve Therapeutics, Inc. Transaction History

Swiss National Bank

$146 Billion
Q4 2024

A detailed history of Swiss National Bank transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 133,100 shares of VERV stock, worth $783,959. This represents 0.0% of its overall portfolio holdings.

Number of Shares

133,100

Previous 115,100 15.64%

Holding current value

$783,959

Previous $557,000 34.65%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	BUY	$4.5 - $7.19 $81,000 - $129,420	18,000 Added 15.64%	133,100 $750,000
Q2 2024 Aug 08, 2024	BUY	$4.76 - $12.79 $56,644 - $152,201	11,900 Added 11.53%	115,100 $561,000
Q1 2024 May 07, 2024	SELL	$10.81 - $17.96 $57,293 - $95,188	-5,300 Reduced 4.88%	103,200 $1.37 Million
Q4 2023 Feb 06, 2024	BUY	$8.84 - $18.7 $116,688 - $246,840	13,200 Added 13.85%	108,500 $1.51 Million
Q3 2023 Nov 08, 2023	BUY	$11.42 - $20.82 $87,934 - $160,314	7,700 Added 8.79%	95,300 $1.26 Million
Q2 2023 Aug 09, 2023	BUY	$13.34 - $19.9 $193,430 - $288,550	14,500 Added 19.84%	87,600 $1.64 Million
Q1 2023 May 10, 2023	SELL	$14.3 - $24.01 $92,950 - $156,065	-6,500 Reduced 8.17%	73,100 $1.05 Million
Q4 2022 Feb 08, 2023	BUY	$17.85 - $40.7 $58,905 - $134,310	3,300 Added 4.33%	79,600 $1.54 Million
Q3 2022 Nov 09, 2022	BUY	$15.63 - $41.49 $482,967 - $1.28 Million	30,900 Added 68.06%	76,300 $2.62 Million
Q2 2022 Aug 09, 2022	BUY	$11.14 - $23.17 $61,270 - $127,435	5,500 Added 13.78%	45,400 $694,000
Q1 2022 May 09, 2022	BUY	$20.92 - $39.36 $62,760 - $118,080	3,000 Added 8.13%	39,900 $911,000
Q4 2021 Feb 08, 2022	BUY	$31.94 - $54.82 $1.18 Million - $2.02 Million	36,900 New	36,900 $1.36 Million

Others Institutions Holding VERV

# of Institutions

180

Shares Held

76.4M

Call Options Held

70.3K

Put Options Held

194K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $353M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Verve Therapeutics, Inc. Transaction History